Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bcl-2 homologous antagonist-killer (BAK1) is a key pro-apoptotic member of the BCL-2 protein family that regulates the intrinsic apoptotic pathway (UniProt Q16611). Located on the outer mitochondrial membrane, BAK1 is activated by BH3-only proteins, prompting it to undergo conformational changes and oligomerize. This oligomerization causes mitochondrial outer membrane permeabilization (MOMP), releasing cytochrome c into the cytosol to initiate caspase-dependent cell death. In oncology, BAK1 expression is frequently downregulated or suppressed by anti-apoptotic proteins, enabling cancer cells to evade apoptosis. Therapeutic agents like BH3 mimetics (e.g., venetoclax, navitoclax) indirectly activate BAK1 by inhibiting its suppressors, such as BCL-2 and BCL-XL, thereby restoring apoptotic signaling in malignancies.
Indirect activation via inhibition of anti-apoptotic BCL-2 family proteins, or direct activation to induce mitochondrial outer membrane permeabilization (MOMP) and subsequent apoptosis.
3 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bcl-2 homologous antagonist-killer (BAK1).